Anita Richard, NP
Acute Care · New Orleans, LANPI 1316042641
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Dexcom, Inc. accounts for 71.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $4,348 and has fallen 79.5% since, to $890 in 2025. Among acute care clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 58 payments — averaging $114.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$5K
- BETA Bionics, Inc.$759
- Medtronic$432
- Abbott$415
- Sequel Med Tech, LLC$165
- Novo Nordisk$125
What the payments were for
- Speaking & faculty fees$2,10032%
- Travel & lodging$1,55123%
- Food & beverage$2,97045%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 22 | $4,725 |
| BETA Bionics, Inc. | 14 | $759 |
| Medtronic | 13 | $432 |
| Abbott | 5 | $415 |
| Sequel Med Tech, LLC | 3 | $165 |
| Novo Nordisk | 1 | $125 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,621 in reported general payments places this provider in the 90th percentile of 248 acute care providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 265 | $324,087 |
| MounjaroTirzepatide | 141 | $157,376 |
| Tresiba Flextouch U-200Insulin Degludec | 151 | $119,755 |
| JardianceEmpagliflozin | 102 | $108,633 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 46 | $90,970 |
| TrulicityDulaglutide | 68 | $87,871 |
| Tresiba Flextouch U-100Insulin Degludec | 136 | $73,198 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $60,421 |
| JanuviaSitagliptin Phosphate | 42 | $55,155 |
| Novolog FlexpenInsulin Aspart | 242 | $53,900 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $35,109 |
| RybelsusSemaglutide | 29 | $34,691 |
| Humalog Kwikpen U-100Insulin Lispro | 102 | $27,513 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 213 | $24,819 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 26 | $24,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $125 | $371,694346 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 248 acute care providers in Louisiana.
Other acute care in New Orleans
- Charles JarreauNew Orleans$40K
- Candita ThompsonNew Orleans$2K
- Erica LoveNew Orleans$2K
- Annie StadstadNew Orleans$2K
- Jennifer FlemingNew Orleans$2K
- Travis KingNew Orleans$2K
- Precious HodgesLafayette$70K
- Brinton FegleyShreveport$61K
- Jeremy DavisShreveport$35K
- Heather MecomShreveport$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.